

USE OF STABLE ISOTOPOMERS AND LIQUID CHROMATOGRAPHY WITH MASS SPECTROMETRY (LC/MS) FOR CARDIAC SUBSTRATE PREFERENCE ANALYSIS IN MICE

Tomczyk Marta¹, Olkowicz Mariola², Słominska Ewa Maria¹, Smolenski Ryszard Tomasz¹

¹ Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland., ² Jagiellonian Centre for Experimental Therapeutics, Krakow, Poland.

OBJECTIVES: Heart is an organ characterized by prominent metabolic flexibility for utilizing all carbon substrates. It is well known that cardiac substrate preference could be coordinated by factors such as the availability of individual substrates, hormonal activity but also might be deregulated in pathological conditions. However, so far there is no simple *in vivo* method to investigate changes in substrates use in cardiac metabolism in mice. Thus, the aim of the study was to develop method for the analysis of cardiac substrate preference using stable ¹³C glucose, ¹³C valine and ¹³C leucine isotopomers as well as LC/MS.

METHODS: Our assay investigated the D-Glucose-1,6-¹³C₂ flux to Pyruvate-3-¹³C as well as the entrance of the Acetyl-CoA-3-¹³C (formed from D-Glucose-1,6-¹³C₂ and L-Leucine-3-¹³C) and Succinyl-CoA-2,3,4-¹³C₃ (formed from L-Valine-¹³C₅) to the Krebs cycle by analysis of Alanine-3-¹³C as well as Glutamate-4-¹³C and Glutamate-1-¹³C enrichment in mice heart (Scheme).

RESULTS AND CONCLUSIONS: After 90 min (D-Glucose-1,6-¹³C₂) or 60 min (L-Leucine-3-¹³C and L-Valine-¹³C₅) of administration mice were anesthetized, intubated and ventilated. Hearts were then freeze-clamped. Blood samples were collected from a tail vein before and after isotopomer injection. Hearts were extracted with perchloric acid while the blood extraction was performed with acetone. The method was validated with inhibitors of glucose and fatty acids metabolism that demonstrated expected shifts in cardiac metabolic substrate use (Figure).

Our method allows fast and simple estimation of cardiac glucose and BCAA use in mice and has potential for analysis of changes in pathology and after pharmacological treatments.





Figure. Glucose use in mice cardiac metabolism after pharmacological treatment A. ¹³C glucose enrichment in mice blood. B. ¹³C glutamate enrichment in heart/ ¹³C glucose enrichment in mice blood ratio. C. ¹³C alanine enrichment in heart / ¹³C enrichment in mice blood ratio. D. ¹³C glutamate/ ¹³C alanine ratio in mice heart. Results presented as mean ± SEM, n=5, * p<0.05, **p<0.01, ***p<0.001.



Scheme of cardiac substrate preference method.